Anti-PD-1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review.
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cisplatin
/ administration & dosage
Doxorubicin
/ administration & dosage
Female
Humans
Lung Neoplasms
/ drug therapy
Middle Aged
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Treatment Outcome
camrelizumab (SHR-1210)
immune checkpoint inhibitors
immunotherapy
programmed cell death ligand 1 (PD-L1)
programmed cell death protein 1 (PD-1)
sarcomatoid carcinoma
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
01
05
2020
accepted:
26
06
2020
pubmed:
11
8
2020
medline:
2
9
2021
entrez:
11
8
2020
Statut:
ppublish
Résumé
Pulmonary sarcomatoid carcinoma (PSC) is characterized by dismal prognosis and resistance to platinum-based chemotherapy. The immune checkpoint inhibitors showed promising efficacy in the treatment of PSC. Camrelizumab is a programmed cell death protein 1 inhibitor; however, current evidence of its efficacy in PSC is lacking. A 47-year-old female non-smoker presented with central-type masses in the right upper and lower lobes. PSC (cT4N2M0, stage IIIB) with positive expression of programmed death ligand-1 was diagnosed. First-line camrelizumab plus doxorubicin and cisplatin was introduced, followed by camrelizumab monotherapy due to grade 4 leukopenia and thrombocytopenia during the combination therapy. The lesions indicated a partial remission which endured for more than 20 months. Camrelizumab plus doxorubicin and cisplatin regimen is a promising option for PSC patients. Further high-quality trials are warranted.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
camrelizumab
73096E137E
Doxorubicin
80168379AG
Cisplatin
Q20Q21Q62J
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1489-1496Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. Surgery. 2012;152:397-402. https://doi.org/10.1016/j.surg.2012.05.007
Schrock AB, Li SD, Frampton GM, et al. Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling. J Thorac Oncol. 2017;12:932-942. https://doi.org/10.1016/j.jtho.2017.03.005
Rahouma M, Kamel M, Narula N, et al. Pulmonary sarcomatoid carcinoma: an analysis of a rare cancer from the Surveillance, Epidemiology, and End Results database. Eur J Cardiothorac Surg. 2018;53:828-834. https://doi.org/10.1093/ejcts/ezx417
Steuer CE, Behera M, Liu Y, et al. Pulmonary sarcomatoid carcinoma: an analysis of the national cancer database. Clin Lung Cancer. 2017;18:286-292. https://doi.org/10.1016/j.cllc.2016.11.016
Baldovini C, Rossi G, Ciarrocchi A. Approaches to tumor classification in pulmonary sarcomatoid carcinoma. Lung Cancer (Auckl). 2019;10:131-149. https://doi.org/10.2147/LCTT.S186779
Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol. 2013;8:1574-1577. https://doi.org/10.1097/01.JTO.0000437008.00554.90
Ung M, Rouquette I, Filleron T, et al. Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung. Clin Lung Cancer. 2016;17:391-397. https://doi.org/10.1016/j.cllc.2016.03.001
Yin J, Yang Y, Ma K, et al. Clinicopathological characteristics and prognosis of pulmonary pleomorphic carcinoma: a population-based retrospective study using SEER data. J Thorac Dis. 2018;10:4262-4273. https://doi.org/10.21037/jtd.2018.06.71
Sun L, Dai J, Chen Y, et al. Pulmonary sarcomatoid carcinoma: experience from seer database and shanghai pulmonary hospital. Ann Thorac Surg. 2020;110(2):406-413. https://doi.org/10.1016/j.athoracsur.2020.02.071
Vieira T, Antoine M, Hamard C, et al. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer. 2016;98:51-58. https://doi.org/10.1016/j.lungcan.2016.05.013
Sukrithan V, Sandler J, Gucalp R, Gralla R, Halmos B. Immune checkpoint blockade is associated with durable responses in pulmonary sarcomatoid carcinoma. Clin Lung Cancer. 2019;20:e242-e246. https://doi.org/10.1016/j.cllc.2018.12.013
Markham A, Keam SJ. Camrelizumab: first global approval. Drugs. 2019;79:1355-1361. https://doi.org/10.1007/s40265-019-01191-0
Lickliter JD, Gan HK, Voskoboynik M, et al. A first-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia. Drug Des Devel Ther. 2020;14:1177-1189. https://doi.org/10.2147/DDDT.S243787
Lancia A, Merizzoli E, Filippi AR. The 8(th) UICC/AJCC TNM edition for non-small cell lung cancer staging: getting off to a flying start? Ann Transl Med. 2019;7(S6):S205. https://doi.org/10.21037/atm.2019.07.02
Maneenil K, Xue Z, Liu M, et al. Sarcomatoid carcinoma of the lung: the Mayo clinic experience in 127 patients. Clin Lung Cancer. 2018;19:e323-e333. https://doi.org/10.1016/j.cllc.2017.12.008
Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34:794-802. https://doi.org/10.1200/JCO.2015.62.0674
Ito K, Hataji O, Katsuta K, et al. "Pseudoprogression" of pulmonary pleomorphic carcinoma during nivolumab therapy. J Thorac Oncol. 2016;11:e117-e119. https://doi.org/10.1016/j.jtho.2016.05.002
Matsumoto Y, Miura T, Horiuchi H, Usui K. The successful treatment of pulmonary pleomorphic carcinoma with pembrolizumab: a case report. Case Rep Oncol. 2017;10:752-757. https://doi.org/10.1159/000479552
Kanazu M, Uenami T, Yano Y, et al. Case series of pleomorphic carcinomas of the lung treated with nivolumab. Thorac Cancer. 2017;8:724-728. https://doi.org/10.1111/1759-7714.12505
Ikematsu Y, Yoneshima Y, Ijichi K, et al. Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1. Lung Cancer. 2017;112:230-231. https://doi.org/10.1016/j.lungcan.2017.07.020
Marchand L, Paulus V, Fabien N, et al. Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response. J Thorac Oncol. 2017;12:e182-e184. https://doi.org/10.1016/j.jtho.2017.07.021
Kodama K, Maniwa T, Kimura Y, et al. Concurrent combination of irradiation and immune checkpoint inhibitor for recurrent pleomorphic carcinoma of the lung. Int Cancer Conf J. 2018;7:43-47. https://doi.org/10.1007/s13691-017-0315-9
Fujimoto E, Yokoi T, Mikami K, et al. Successful treatment of pulmonary pleomorphic carcinoma with nivolumab: a case report. Case Rep Oncol. 2018;11:336-340. https://doi.org/10.1159/000489392
Yoshimura A, Takumi C, Tsuji T, et al. Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: a case report. Clin Case Rep. 2018;6:1338-1341. https://doi.org/10.1002/ccr3.1627
Okamura K, Fukuda Y, Soda H, et al. Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab. Thorac Cancer. 2018;9:193-196. https://doi.org/10.1111/1759-7714.12557
Kawamata O, Murata T, Uda M. Pulmonary pleomorphic carcinoma relapsed after surgery surviving long-term by chemotherapy and nivolumab. Kyobu Geka. 2018;71:329-333.
Tozuka T, Sugano T, Noro R, et al. Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. Oxf Med Case Reports. 2018;2018:omy094. https://doi.org/10.1093/omcr/omy094
Salati M, Baldessari C, Calabrese F, et al. Nivolumab-induced impressive response of refractory pulmonary sarcomatoid carcinoma with brain metastasis. Case Rep Oncol. 2018;11:615-621. https://doi.org/10.1159/000492666
Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29:2085-2091. https://doi.org/10.1093/annonc/mdy334
Domblides C, Monnet I, Mazieres J, et al. Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: data from a French multicentric cohort. Ann Oncol. 2018;29(Suppl 8):viii400-viii441.
Liu B, Li Y, Zhang Y, Wan Y, Lang Y, Wang Y. Pembrolizumab in a patient with lung sarcomatoid carcinoma resulted in rheumatoid arthritis and limited benefit. Int J Clin Exp Med. 2018;11:13897-13900.
Yaguchi D, Ichikawa M, Ito M, Okamoto S, Kimura H, Watanabe K. Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence. Thorac Cancer. 2019;10:1263-1266. https://doi.org/10.1111/1759-7714.13029
Senoo S, Ninomiya T, Makimoto G, et al. Rapid and long-term response of pulmonary pleomorphic carcinoma to nivolumab. Intern Med. 2019;58:985-989. https://doi.org/10.2169/internalmedicine.0890-18
Honjo O, Kubo T, Sugaya F, et al. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer. 2019;7:97. https://doi.org/10.1186/s40425-019-0582-4
Naito M, Tamiya A, Takeda M, et al. A high PD-L1 expression in pulmonary pleomorphic carcinoma correlates with parietal-pleural invasion and might predict a poor prognosis. Intern Med. 2019;58:921-927. https://doi.org/10.2169/internalmedicine.1462-18
Ota T, Niho S, Kirita K, Ishii G, Tsuboi M, Goto K. Impressive response to nivolumab of non-small-cell lung cancer containing sarcomatoid components. Respirol Case Rep. 2019;7:e00477. https://doi.org/10.1002/rcr2.477
Tokuyasu H, Ishikawa S, Sakai H, Ikeuchi T, Miura H. Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma. Respir Med Case Rep. 2019;28:100879. https://doi.org/10.1016/j.rmcr.2019.100879
Kotlowska MP, Rueda AG, Olmedo ME, et al. Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review. Respir Med Case Rep. 2019;26:310-314. https://doi.org/10.1016/j.rmcr.2019.02.017
Roesel C, Kambartel K, Kopeika U, Berzins A, Voshaar T, Krbek T. Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung. Curr Oncol. 2019;26:e270-e273. https://doi.org/10.3747/co.26.4377
Song P, Zhang J, Zhang L. Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer. Onco Targets Ther. 2019;12:2943-2948. https://doi.org/10.2147/OTT.S203192
D'Antonio F, De Sanctis R, Bolengo I, et al. Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity: A case report on the therapeutic regimen. Medicine (Baltimore). 2019;98:e16754. https://doi.org/10.1097/MD.0000000000016754
Takahashi T, Tateishi A, Bychkov A, Fukuoka J. Remarkable alteration of PD-L1 expression after immune checkpoint therapy in patients with non-small-cell lung cancer: two autopsy case reports. Int J Mol Sci. 2019;20:2578. https://doi.org/10.3390/ijms20102578
Signorelli D, Ferrara R, Proto C, et al. Immune-checkpoints inhibitors in metastatic non small cell lung cancer with rare histology. J Clin Oncol. 2019;37(Suppl):abstr9106. https://doi.org/10.1200/jco.2019.37.15_suppl.9106
Babacan NA, Pina IB, Signorelli D, Prelaj A, Garassino MC, Tanvetyanon T. Relationship between programmed death receptor-ligand 1 expression and response to checkpoint inhibitor immunotherapy in pulmonary sarcomatoid carcinoma: a pooled analysis. Clin Lung Cancer. 2020; https://doi.org/10.1016/j.cllc.2020.02.022. [Epub ahead of print].
Cimpeanu E, Ahmed J, Zafar W, et al. Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: a case report. World J Clin Cases. 2020;8:97-102. https://doi.org/10.12998/wjcc.v8.i1.97
Nishino K, Kunimasa K, Kimura M, et al. Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report. BMC Pharmacol Toxicol. 2020;21:26. https://doi.org/10.1186/s40360-020-00404-7
Domblides C, Leroy K, Monnet I, et al. Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma. J Thorac Oncol. 2020;15:860-866. https://doi.org/10.1016/j.jtho.2020.01.014
Yorozuya T, Taya T, Yasuda K, et al. Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: a case report. Thorac Cancer. 2020;11:1090-1093. https://doi.org/10.1111/1759-7714.13331
Lococo F, Gandolfi G, Rossi G, et al. Deep sequencing analysis reveals that KRAS mutation is a marker of poor prognosis in patients with pulmonary sarcomatoid carcinoma. J Thorac Oncol. 2016;11:1282-1292. https://doi.org/10.1016/j.jtho.2016.04.020
Yang Z, Xu J, Li R, Gao Y, He J. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. J Cancer Res Clin Oncol. 2019;145:3055-3065. https://doi.org/10.1007/s00432-019-03023-w
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-168. https://doi.org/10.1056/NEJMra1703481